International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.
作者信息
Singal Amit G, Hoshida Yujin, Pinato David J, Marrero Jorge, Nault Jean-Charles, Paradis Valerie, Tayob Nabihah, Sherman Morris, Lim Young Suk, Feng Ziding, Lok Anna S, Rinaudo Jo Ann, Srivastava Sudhir, Llovet Josep M, Villanueva Augusto
机构信息
Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, Texas.
Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, Texas.
出版信息
Gastroenterology. 2021 Jun;160(7):2572-2584. doi: 10.1053/j.gastro.2021.01.233. Epub 2021 Mar 9.
Abstract
摘要
相似文献
1
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.国际肝癌协会（ILCA）关于肝细胞癌生物标志物开发的白皮书。
Gastroenterology. 2021 Jun;160(7):2572-2584. doi: 10.1053/j.gastro.2021.01.233. Epub 2021 Mar 9.
2
A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis.一种用于肝硬化患者肝细胞癌早期检测和风险评估的新型生物标志物组合。
Cancer Prev Res (Phila). 2021 Jun;14(6):667-674. doi: 10.1158/1940-6207.CAPR-20-0600. Epub 2021 Mar 8.
3
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.GALAD 在肝硬化患者队列中对 HCC 监测具有很高的灵敏度。
Hepatology. 2022 Mar;75(3):541-549. doi: 10.1002/hep.32185. Epub 2021 Dec 17.
4
Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma.去γ-羧基凝血酶原是甲胎蛋白阴性的乙型肝炎病毒相关肝细胞癌早期诊断的良好生物标志物。
J Int Med Res. 2020 Feb;48(2):300060520902575. doi: 10.1177/0300060520902575.
5
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis.用于肝硬化中肝细胞癌风险分层的PAaM的3期验证
Gastroenterology. 2025 Mar;168(3):556-567.e7. doi: 10.1053/j.gastro.2024.10.035. Epub 2024 Nov 8.
6
Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma.分子信标检测连接脂复合物纳米粒中细胞外 mRNA 用于诊断人肝细胞癌。
PLoS One. 2018 Jun 7;13(6):e0198552. doi: 10.1371/journal.pone.0198552. eCollection 2018.
7
A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse.一个在肝细胞癌中重新出现的预后标志物：捕捞 c-myc 基因对早期复发的附加价值。
PLoS One. 2013 Jul 10;8(7):e68203. doi: 10.1371/journal.pone.0068203. Print 2013.
8
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肝细胞癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.
9
Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.基于多种“组学”数据的生物标志物筛选用于肝细胞癌诊断。
World J Gastroenterol. 2019 Aug 14;25(30):4199-4212. doi: 10.3748/wjg.v25.i30.4199.
10
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.2000 - 2010年美国纤维板层型肝细胞癌的流行病学
Gut. 2013 Nov;62(11):1667-8. doi: 10.1136/gutjnl-2013-305164. Epub 2013 May 25.
引用本文的文献
1
A serum TNFR2-based model effectively predicates preoperative microvascular invasion and stratifies the tumor recurrence risk in hepatocellular carcinoma.一种基于血清肿瘤坏死因子受体2（TNFR2）的模型可有效预测术前微血管侵犯，并对肝细胞癌的肿瘤复发风险进行分层。
BMC Gastroenterol. 2025 Aug 27;25(1):622. doi: 10.1186/s12876-025-04152-y.
2
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.新兴监测选项背景下肝癌监测的价值：多利益相关方改良德尔菲小组的观点
Hepatology. 2025 Sep 1;82(3):794-809. doi: 10.1097/HEP.0000000000001203. Epub 2024 Dec 18.
3
The Search for Prognostic Biomarkers in Patients with Surgically Treated Hepatocellular Carcinoma.手术治疗肝细胞癌患者预后生物标志物的探索
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102599. doi: 10.1016/j.jceh.2025.102599. Epub 2025 May 24.
4
Pyroptosis drives tumor progression and immune evasion in Hepatocellular Carcinoma: a single-cell and spatial transcriptomic study.细胞焦亡促进肝细胞癌的肿瘤进展和免疫逃逸：一项单细胞和空间转录组学研究
Discov Oncol. 2025 May 20;16(1):834. doi: 10.1007/s12672-025-02421-6.
5
Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinoma.简化磁共振成像（MRI）和超声用于检测早期肝细胞癌的多中心评估
JHEP Rep. 2025 Feb 12;7(5):101357. doi: 10.1016/j.jhepr.2025.101357. eCollection 2025 May.
6
Superior Diagnostic Yield of Core Needle Biopsy Over Fine Needle Aspiration in Diagnosing Follicular-Patterned Neoplasms: A Multicenter Study Focusing on Bethesda IV Results.在诊断滤泡型肿瘤中，粗针活检的诊断效能优于细针穿刺抽吸：一项聚焦于贝塞斯达IV级结果的多中心研究
Korean J Radiol. 2025 Jun;26(6):604-615. doi: 10.3348/kjr.2024.1022. Epub 2025 Apr 17.
7
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.去γ-羧基凝血酶原在肝细胞癌术后复发风险评估中的应用
Commun Med (Lond). 2025 Mar 6;5(1):65. doi: 10.1038/s43856-025-00784-z.
8
Persisting challenges in the early detection of hepatocellular carcinoma.肝细胞癌早期检测中持续存在的挑战。
Expert Rev Anticancer Ther. 2025 Feb 24:1-12. doi: 10.1080/14737140.2025.2467184.
9
Liver diseases: epidemiology, causes, trends and predictions.肝脏疾病：流行病学、病因、趋势及预测
Signal Transduct Target Ther. 2025 Feb 5;10(1):33. doi: 10.1038/s41392-024-02072-z.
10
Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.一种用于监测男性代谢功能障碍相关脂肪性肝病向肝细胞癌进展的新型四基因模型的开发。
J Cancer. 2025 Jan 1;16(3):917-931. doi: 10.7150/jca.100724. eCollection 2025.
本文引用的文献
1
Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis.患者报告的障碍与肝硬化患者多中心队列中接受肝细胞癌监测的情况相关。
Clin Gastroenterol Hepatol. 2021 May;19(5):987-995.e1. doi: 10.1016/j.cgh.2020.06.049. Epub 2020 Jul 3.
2
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.肝细胞癌的试验设计与终点：美国肝病研究学会共识会议
Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.
3
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
4
Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.肝细胞癌肿瘤体积倍增时间：系统评价和荟萃分析。
Gut. 2021 Feb;70(2):401-407. doi: 10.1136/gutjnl-2020-321040. Epub 2020 May 12.
5
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.应用于肝硬化患者的肝细胞癌监测：一项系统评价和荟萃分析。
Hepatology. 2021 Feb;73(2):713-725. doi: 10.1002/hep.31309. Epub 2020 Nov 20.
6
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.肝细胞癌在肝硬化多中心队列患者中表现出异质性生长模式。
Hepatology. 2020 Nov;72(5):1654-1665. doi: 10.1002/hep.31159. Epub 2020 Oct 25.
7
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.AGA 临床实践更新：非酒精性脂肪性肝病患者肝细胞癌的筛查和监测：专家综述。
Gastroenterology. 2020 May;158(6):1822-1830. doi: 10.1053/j.gastro.2019.12.053. Epub 2020 Jan 30.
8
Advances in molecular classification and precision oncology in hepatocellular carcinoma.肝细胞癌的分子分类和精准肿瘤学进展。
J Hepatol. 2020 Feb;72(2):215-229. doi: 10.1016/j.jhep.2019.08.017.
9
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.BLU-554 单药治疗肝细胞癌的首次人体 I 期临床试验结果：异常 FGF19 信号通路激活可作为驱动事件
Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.
10
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.慢性肝病和肝硬化的当代流行病学。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666. doi: 10.1016/j.cgh.2019.07.060. Epub 2019 Aug 8.
Zotero 插件